meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

NCT05715814 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Peritoneal Dialysis Complication
End Stage Kidney Disease
Sodium-glucose Co-transporter-2 Inhibitors
Kidney Dysfunction
Residual Kidney Function

Interventions

DRUG: Empagliflozin 25 MG

Sponsor

University Health Network, Toronto